Cargando…

Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors

Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Beatriz Guerreiro Ruiz, Souza, Cristiano de Pádua, Andrade, Carlos Eduardo Mattos da Cunha, Vieira, Marcelo de Andrade, Andrade, Diocésio Alves Pinto de, Reis, Ricardo dos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309283/
https://www.ncbi.nlm.nih.gov/pubmed/31344718
http://dx.doi.org/10.1055/s-0039-1693056
_version_ 1785066418697404416
author Castro, Beatriz Guerreiro Ruiz
Souza, Cristiano de Pádua
Andrade, Carlos Eduardo Mattos da Cunha
Vieira, Marcelo de Andrade
Andrade, Diocésio Alves Pinto de
Reis, Ricardo dos
author_facet Castro, Beatriz Guerreiro Ruiz
Souza, Cristiano de Pádua
Andrade, Carlos Eduardo Mattos da Cunha
Vieira, Marcelo de Andrade
Andrade, Diocésio Alves Pinto de
Reis, Ricardo dos
author_sort Castro, Beatriz Guerreiro Ruiz
collection PubMed
description Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15–71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presented with virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138–569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1–11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0–2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7–3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1–147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2–23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation of Gynecology and Obstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of them underwent 3 cycles of paclitaxel and carboplatin every 21 days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.
format Online
Article
Text
id pubmed-10309283
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Thieme Revinter Publicações Ltda
record_format MEDLINE/PubMed
spelling pubmed-103092832023-07-27 Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors Castro, Beatriz Guerreiro Ruiz Souza, Cristiano de Pádua Andrade, Carlos Eduardo Mattos da Cunha Vieira, Marcelo de Andrade Andrade, Diocésio Alves Pinto de Reis, Ricardo dos Rev Bras Ginecol Obstet Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15–71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presented with virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138–569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1–11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0–2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7–3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1–147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2–23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation of Gynecology and Obstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of them underwent 3 cycles of paclitaxel and carboplatin every 21 days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred. Thieme Revinter Publicações Ltda 2019-07-10 2019-07 /pmc/articles/PMC10309283/ /pubmed/31344718 http://dx.doi.org/10.1055/s-0039-1693056 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Castro, Beatriz Guerreiro Ruiz
Souza, Cristiano de Pádua
Andrade, Carlos Eduardo Mattos da Cunha
Vieira, Marcelo de Andrade
Andrade, Diocésio Alves Pinto de
Reis, Ricardo dos
Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors
title Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors
title_full Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors
title_fullStr Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors
title_full_unstemmed Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors
title_short Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors
title_sort ovarian sertoli-leydig cell tumors: epidemiological, clinical and prognostic factors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309283/
https://www.ncbi.nlm.nih.gov/pubmed/31344718
http://dx.doi.org/10.1055/s-0039-1693056
work_keys_str_mv AT castrobeatrizguerreiroruiz ovariansertolileydigcelltumorsepidemiologicalclinicalandprognosticfactors
AT souzacristianodepadua ovariansertolileydigcelltumorsepidemiologicalclinicalandprognosticfactors
AT andradecarloseduardomattosdacunha ovariansertolileydigcelltumorsepidemiologicalclinicalandprognosticfactors
AT vieiramarcelodeandrade ovariansertolileydigcelltumorsepidemiologicalclinicalandprognosticfactors
AT andradediocesioalvespintode ovariansertolileydigcelltumorsepidemiologicalclinicalandprognosticfactors
AT reisricardodos ovariansertolileydigcelltumorsepidemiologicalclinicalandprognosticfactors